Application of Cyclodextrin for Cancer Immunotherapy.


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
24 Jul 2023
Historique:
received: 13 03 2023
revised: 21 07 2023
accepted: 21 07 2023
medline: 31 7 2023
pubmed: 29 7 2023
entrez: 29 7 2023
Statut: epublish

Résumé

Tumor immunotherapy, compared with other treatment strategies, has the notable advantage of a long-term therapeutic effect for preventing metastasis and the recurrence of tumors, thus holding great potential for the future of advanced tumor therapy. However, due to the poor water solubility of immune modulators and immune escape properties of tumor cells, the treatment efficiency of immunotherapy is usually significantly reduced. Cyclodextrin (CD) has been repeatedly highlighted to be probably one of the most investigated building units for cancer therapy due to its elegant integration of an internal hydrophobic hollow cavity and an external hydrophilic outer surface. The application of CD for immunotherapy provides new opportunities for overcoming the aforementioned obstacles. However, there are few published reviews, to our knowledge, summarizing the use of CD for cancer immunotherapy. For this purpose, this paper provides a comprehensive summary on the application of CD for immunotherapy with an emphasis on the role, function, and reported strategies of CD in mediating immunotherapy. This review summarizes the research progress made in using CD for tumor immunotherapy, which will facilitate the generation of various CD-based immunotherapeutic delivery systems with superior anticancer efficacy.

Identifiants

pubmed: 37513483
pii: molecules28145610
doi: 10.3390/molecules28145610
pmc: PMC10384645
pii:
doi:

Substances chimiques

Cyclodextrins 0
Immunologic Factors 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Outstanding Youth Fund of Natural Science Foundation of Hunan province
ID : 2017JJ1024

Références

Int J Mol Sci. 2023 Feb 11;24(4):
pubmed: 36835054
Carbohydr Polym. 2023 Feb 1;301(Pt B):120365
pubmed: 36446487
Cancer Commun (Lond). 2021 Sep;41(9):803-829
pubmed: 34165252
J Oncol. 2019 Feb 28;2019:4508794
pubmed: 30941175
Nano Lett. 2017 Oct 11;17(10):6366-6375
pubmed: 28858519
J Mater Chem B. 2021 Sep 22;9(36):7347-7370
pubmed: 34382629
Br J Cancer. 2019 Apr;120(9):871-882
pubmed: 30936499
Molecules. 2022 Oct 13;27(20):
pubmed: 36296441
Expert Opin Drug Deliv. 2021 Aug;18(8):1067-1090
pubmed: 33507117
Cancer Immunol Immunother. 2013 Mar;62(3):405-10
pubmed: 23423351
Drug Deliv. 2021 Dec;28(1):2594-2602
pubmed: 34866536
Sci Adv. 2020 Sep 4;6(36):
pubmed: 32917616
ACS Appl Mater Interfaces. 2022 Sep 14;14(36):40612-40623
pubmed: 36053499
RSC Med Chem. 2021 Jan 21;12(3):406-409
pubmed: 34046623
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
PLoS One. 2018 Jan 24;13(1):e0191766
pubmed: 29364966
Angew Chem Int Ed Engl. 2019 Sep 9;58(37):12988-12993
pubmed: 31206941
Int J Mol Med. 2017 Mar;39(3):507-518
pubmed: 28098857
Adv Mater. 2021 Feb;33(7):e2007293
pubmed: 33448050
Cold Spring Harb Symp Quant Biol. 1989;54 Pt 1:529-43
pubmed: 2700944
Cell Rep. 2019 Oct 29;29(5):1221-1235.e5
pubmed: 31665635
J Clin Invest. 2015 Sep;125(9):3338-46
pubmed: 26241053
Acta Pharm Sin B. 2022 Jan;12(1):378-393
pubmed: 35127393
Nanoscale. 2020 Jan 2;12(2):413-436
pubmed: 31829394
Sci Bull (Beijing). 2022 Sep 30;67(18):1898-1909
pubmed: 36546304
Biomacromolecules. 2009 Dec 14;10(12):3157-75
pubmed: 19921854
Curr Drug Targets. 2020;21(14):1495-1510
pubmed: 32538725
Molecules. 2019 Mar 18;24(6):
pubmed: 30889860
Biomacromolecules. 2021 Feb 8;22(2):732-742
pubmed: 33331770
ACS Nano. 2010 Jul 27;4(7):4001-10
pubmed: 20583782
J Immunother Cancer. 2018 Jun 20;6(1):61
pubmed: 29921320
Clin Cancer Res. 2015 Dec 15;21(24):5427-33
pubmed: 26519060
Nano Lett. 2018 May 9;18(5):3250-3258
pubmed: 29683683
Int Rev Immunol. 2023;42(2):113-138
pubmed: 34494938
Nat Commun. 2016 Nov 07;7:13443
pubmed: 27819653
Acta Pharm Sin B. 2022 Dec;12(12):4327-4347
pubmed: 36561994
Sci Transl Med. 2018 Mar 21;10(433):
pubmed: 29563317
J Clin Oncol. 2019 Dec 20;37(36):3546-3555
pubmed: 31675272
Eur J Pharm Sci. 2023 Jun 1;185:106427
pubmed: 36948408
Int J Pharm. 2020 Jun 15;583:119396
pubmed: 32376442
Nat Rev Clin Oncol. 2020 Nov;17(11):657-674
pubmed: 32699309
Annu Rev Immunol. 2015;33:445-74
pubmed: 25622193
Cancer Discov. 2015 Jan;5(1):16-8
pubmed: 25583798
Adv Healthc Mater. 2019 Jul;8(13):e1900132
pubmed: 31067008
ACS Appl Mater Interfaces. 2022 Sep 21;14(37):41834-41850
pubmed: 36073504
ACS Appl Bio Mater. 2020 May 18;3(5):3326-3336
pubmed: 35025375
Adv Funct Mater. 2020 Apr 20;30(16):
pubmed: 33071710
Hum Pathol. 2018 May;75:81-90
pubmed: 29447919
Expert Opin Drug Saf. 2013 Sep;12(5):631-45
pubmed: 23668362
Int J Pharm. 2022 Jul 25;623:121940
pubmed: 35724824
Cancers (Basel). 2016 Mar 05;8(3):
pubmed: 26959063
Nat Rev Cancer. 2014 Feb;14(2):135-46
pubmed: 24457417
Nat Rev Immunol. 2004 Oct;4(10):762-74
pubmed: 15459668
Oncoscience. 2015 Aug 31;2(10):845-6
pubmed: 26682274
Biochem Pharmacol. 1996 Nov 22;52(10):1537-44
pubmed: 8937468
Blood. 2009 Mar 12;113(11):2394-401
pubmed: 19023117
Crit Rev Food Sci Nutr. 2022;62(10):2627-2640
pubmed: 33320702
J Control Release. 2021 Aug 10;336:621-634
pubmed: 34246701
Acta Biomater. 2021 Oct 1;133:257-267
pubmed: 34407475
Front Pharmacol. 2023 Apr 21;14:1152934
pubmed: 37153795
Angew Chem Int Ed Engl. 2023 Feb 20;62(9):e202214659
pubmed: 36577087
Eur J Pharm Sci. 2019 Oct 1;138:105034
pubmed: 31382032
Pharmaceutics. 2023 Jan 21;15(2):
pubmed: 36839691
Sci Transl Med. 2013 Aug 28;5(200):200ra116
pubmed: 23986400
Int J Biochem Cell Biol. 2021 Aug;137:106016
pubmed: 34082133
Nat Biomed Eng. 2018 Aug;2(8):578-588
pubmed: 31015631
Biomolecules. 2022 Apr 25;12(5):
pubmed: 35625562
Pharmaceutics. 2022 Aug 22;14(8):
pubmed: 36015374
Ther Adv Med Oncol. 2019 Oct 13;11:1758835919878347
pubmed: 31662796
Carbohydr Polym. 2018 Feb 15;182:75-80
pubmed: 29279128
Molecules. 2019 Jun 14;24(12):
pubmed: 31207901

Auteurs

Xiaojie Wei (X)

Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, University of South China, Hengyang 421001, China.

Cui-Yun Yu (CY)

Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, University of South China, Hengyang 421001, China.

Hua Wei (H)

Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, University of South China, Hengyang 421001, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH